Sedation for fibreoptic bronchoscopy
The fibreoptic bronchoscope has extended the range of examination of the bronchial tree and increased the ease with which the examination can be carried out. With this has come the realisation that the procedure has its risks. The various audits of bronchoscopic practice'" have reported mortality rates of 001-0-5% and major complication rates of 0-08-5% (table 1) . Most deaths and complications arise from the procedure itself, but at least five deaths and up to half of the major life threatening complications have been related to the sedative regimen used. Deaths associated with sedation for endoscopy but due to other causes (for example, tension pneumothorax) are reported separately.78 This has led to an increased awareness of the need for a satisfactory sedative regimen for bronchoscopy.
Techniques available
Fibreoptic bronchoscopy may be performed without sedation269 and in one study this technique was found to be very acceptable to patients.9 In another study, however, 60% of patients reported their bronchoscopy without sedation as very unpleasant or intolerable.'°Standard bronchoscopic practice in the United Kingdom includes some sedative regimen. Of 227 physicians routinely performing fibreoptic bronchoscopy, only 6% routinely used no sedative.6 Drugs were given as parenteral premedication by 47% and as intravenous sedation during the procedure by 17%; 19% used both premedication and intraoperative sedation and 12% administered a general anaesthetic. Local anaesthesia should provide the necessary analgesia for bronchoscopy when benzodiazepine is used for sedation. The safe dose of lignocaine for infiltration is 3 mg/kg, toxicity being associated with a plasma concentration of 5 pg/ml. A survey of British bronchoscopists showed that the average dose of lignocaine used was 342 (range 100-960) mg and the maximum dose 368 (range 100-1180) mg.6 Some studies have suggested that doses higher than those recommended may be safe62' as much of the administered lignocaine may be swallowed or aspirated by suction.In these three studies peak plasma concentrations of lignocaine occurred between five and 90 minutes after administration and plasma concentrations of lignocaine above the toxic limit were seen in patients with impaired liver function. The recommended dose of 3 mg/kg should not be exceeded in patients with liver disease, and any patient receiving more than this dose should be closely monitored for at least 90 minutes after the procedure.
Reversal of sedation
The availability of specific antagonists for both opioids and benzodiazepines has led to their use in reversing sedation after endoscopy. The advantages of this technique are that the patient is rapidly awake and self caring and has a better comprehension of any postoperative instruction. It also reduces the need for recovery time and facilities. Some dangers, however, are inherent in this technique. Both flumazenil and naloxone have short half lives. The half life of flumazenil is less than half that of midazolam in normal subjects and considerably less in individuals who are slow metabolisers. There is therefore a risk of resedation when the action of flumazenil ends. This risk is greater ifflumazenil is used to reverse the action of diazepam' or if the reversal agent is given intravenously after intramuscular administration of the agonist. Resedation with opioids after reversal with naloxone is almost inevitable as most of the opioids used have an elimination half life two to three times that of naloxone. Another danger with the use of reversal agents is the temptation to use higher doses of agonist to achieve perfect conditions. This has already been suggested for midazolam" but is likely to result in an increased incidence and severity of side effects.8
Ifthese dangers are appreciated, reversal ofsedation may be appropriate after bronchoscopy but it should not be used to compensate for inadequate recovery facilities. The patient should still be observed closely in a recovery area, criteria for discharge should not be relaxed, and antagonists should not be given to patients already taking benzodiazepines or opioids in case a withdrawal reaction is precipitated.88 772 
Safety
The safety of sedation for bronchoscopy depends not only on the agents used but also on the way their effects are monitored and on the facilities and personnel available. Dental practitioners have strict criteria for the level of staffing and the equipment necessary before drugs producing conscious sedation are administered. Bronchoscopy is usually performed within hospitals with resuscitation teams available and criteria are less formalised; similar standards should nevertheless apply.
PREOPERATIVE ASSESSMENT Some preoperative assessment and investigation ofthe patient is required to detect risk factors,'2 correct anaemia or cardiac failure,72 and assess the need for sedation. As aspiration of gastric contents may occur during or after bronchoscopy, patients should be starved for at least four hours before the procedurethough 15% of British bronchoscopists did not routinely starve patients.6 In this study6 only 27% routinely established intravenous access before the procedure.
EQUIPMENT A full range of resuscitation equipment should be immediately available. This equipment should be checked frequently and should allow for head down tilt and pharyngeal suction, for additional oxygen to be administered, for the patient's airway to be controlled, for the patient to have assisted ventilation, and for cardiac arrythmias to be appropriately treated. Equipment for emergency endotracheal intubation was not available to 13% of bronchoscopists and a defibrillator was not After bronchoscopy patients should recover under supervision until ready to go back to the ward or home. Day case patients should fulfil street fitness criteria before discharge. They should be accompanied by a responsible adult and warned not to drink alcohol and not to drive or operate heavy machinery for 24 hours.
Conclusion
The number of patients requiring fibreoptic bronchoscopy has increased rapidly and a sedative regimen for the procedure must be safe in a wide range of circumstances. Although anaesthetists have limited experience of sedation for fibreoptic bronchoscopy, they have extensive experience of sedation for other procedures as well as an in depth practical and theoretical knowledge of the drugs concerned. We hope that some of this knowledge may be useful to doctors carrying out bronchoscopy. 
